IL17A and Alzheimer disease: Previous studies have reported that patients with higher IL-17 levels tend to respond more favorably to MSC therapy, suggesting the need for further research to determine whether IL-17 could serve as an effective biomarker for selecting MSC treatment in moderate to severe AD cases, as well as for long-term observational studies on MSC therapy [19].